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epressive disorders are a leading cause of dis-
ability worldwide.
1,2 By the year 2020, unipolar major
depression is projected to be the second leading cause of
disability-adjusted life years (DALYS) all over the world.
1
Depressive disorders greatly impact morbidity, health
care utilization,and medical costs.
Despite advances in psychopharmacology and the
reported high rates of treatment success (usually between
50% and 70%),the general rule of thumb is that less than
half of patients beginning a course of antidepressant treat-
ment will reach remission with that treatment.
3This implies
that a significant proportion of depressed patients either
do not respond or continue to have residual symptoms
despite treatment with antidepressants.Major depression
that does not resolve with adequate antidepressant treat-
ment is termed treatment-resistant depression (TRD).
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There is no universally accepted definition for TRD.
Several criteria have been suggested,including failure of
at least one adequate antidepressant trial,two adequate
antidepressant trials, a trial with a monoamine oxidase
inhibitor, lithium, or the newer heterocyclics, or at least
one trial of electroconvulsive therapy (ECT).
4 However,
failure of at least one adequate antidepressant trial
appears to be emerging as the consensus operational cri-
terion for TRD.
5 Long-term studies indicate that 20% of
patients with major depression remain unwell 2 years
after the onset of the illness.
6
TRD is associated with extensive use of depression-
related and general medical services, and poses a sub-
stantial economic burden. The psychiatrist managing
these patients is faced with therapeutic challenges and
dilemmas.Several management strategies have been sug-
gested for patients with resistant depression,but there is
no definite algorithm for treatment.However,research in
this area has advanced considerably and has the potential
to enhance our understanding about the diagnostic and
therapeutic aspects of resistant depression.
We review some of the terms used to define TRD, its
prevalence,etiology,and impact on the patient and soci-
ety, and current approaches in management, including
antidepressant treatment strategies.
Review of TRD terminology
• Absolute and relative treatment resistance. Absolute
treatment resistance is defined as failure to respond to
one adequate antidepressant trial (ie,20-40 mg fluoxe-
tine or its equivalent,or 4 weeks of 150 mg imipramine
or its equivalent) and relative treatment resistance is
defined as nonresponse to an inadequate treatment.
5,7
• Treatment-refractory depression.This is defined as fail-
ure to respond to two drugs of different pharmacolog-
ical classes,each used in an adequate dose for an ade-
quate duration.
8
• Adequate dose.This is defined as the standard recom-
mended dose of the antidepressant (significantly supe-
rior to placebo in double-blind trials).
5
• Adequate duration of treatment.Adequate duration of
treatment is defined as at least four consecutive weeks
of treatment,during which the patient has had an ade-
quate dose for at least 3 weeks.
5
• Response.Response is defined as a ≥50% reduction in
the Hamilton Rating Scale for Depression (HAM-D)
score, a posttreatment HAM-D score of ≤7 or a score
of ≤2 (ie, much improved) on the Clinical Global
Impressions (CGI) scale.
8
• Remission,recovery,relapse,and recurrence.Remission
is defined as a period during which the patient is asymp-
tomatic (with a 17-item HAM-D [HAM-D-17] score
≤7), lasting >2 weeks, but <6 months. Recovery is a
period of remission >6 months. Return of depressive
symptoms meeting criteria for major depression during
the period of remission is termed relapse;if it occurs dur-
ing the recovery period,it is termed recurrence.
9-11 
Factors contributing to TRD
TRD is likely to be due to multiple factors.These can
broadly be divided into factors related to the illness,fac-
tors related to treatment, and patient and environmen-
tal factors.However,usually,a combination of these fac-
tors are involved in treatment resistance.
Factors related to the illness
Unrecognized comorbid medical illness either causing or
exacerbating psychiatric syndromes can occur in up to
46% of psychiatric inpatients
12 and can contribute to
TRD.These include hypercholesterolemia, endocrine
disorders, such as hypothyroidism, subclinical hypothy-
roidism, diabetes, and Cushing’s syndrome, Parkinson’s
disease, Huntington’s disease, dementia, cerebrovascu-
lar disease,and seizure disorder.
13,14 Comorbid psychiatric
disorders, such as bipolar disorder, substance abuse or
dependence,eating disorders,obsessive-compulsive dis-
order, and panic disorder, may also contribute to treat-
ment resistance.
5,15
An association between treatment resistance and 
specific depressive subtypes has been reported by
researchers.
5Atypical depression with panic may be rela-
tively resistant to tricyclic antidepressants (TCAs),but
responsive to monoamine oxidase inhibitors (MAOIs).
16
Selected abbreviations and acronyms
CGI  Clinical Global Impressions (scale)
ECT electroconvulsive therapy
HAM-D Hamilton Rating Scale for Depression
MAOI monoamine oxidase inhibitor
SSRI selective serotonin reuptake inhibitor
T3 triiodothyronine
TCA tricyclic antidepressant
TRD treatment-resistant depressionPsychotic and melancholic depression may also be resis-
tant to treatment,requiring the use of additional treat-
ment strategies.Factors such as greater number of somatic
symptoms and reported history of childhood emotional
abuse and sequelae of that abuse may be associated with
treatment resistance in depressed outpatients.
17,18
Factors related to antidepressant treatment
Up to 20% of patients who are termed treatment resis-
tant may actually be intolerant to the medication.
19The use
of concomitant medications may interfere with the absorp-
tion and metabolism of antidepressants,and interfere with
response. Inadequate treatment of earlier episodes may
lead to treatment resistance possibly due to kindling and
sensitization at the receptor and synaptic levels.
20
Factors related to the patient and environment
These include partial compliance or noncompliance,rapid
metabolism,and the presence of severe psychosocial stres-
sors.Partial compliance or noncompliance are important
causes of treatment resistance,as up to 50% of patients do
not take the medication as prescribed, and tend to stop
treatment when symptoms remit.
7 Individual differences in
drug metabolism may result in suboptimal blood levels in
patients who are rapid metabolizers and contribute to
treatment resistance.
7 Nutritional status of the patient must
be assessed,as deficiencies in folate,thiamine,vitamin B6,
vitamin B12,copper,and zinc may contribute to treatment
resistance.
21,22The presence of psychosocial stressors and
the relative absence of family support may also predict
poor outcome for depressed patients.
23
Brain imaging studies
Although neuroimaging is a useful tool to assess brain
function in depression,few published brain imaging stud-
ies have compared brain function in TRD and treatment-
responsive or non–treatment-resistant depression (non-
TRD). Shah and coworkers found that patients with
chronic TRD had reduced gray matter density in the left
temporal cortex including the hippocampus,with a trend
toward reduction in the right hippocampus.
24 These
authors also reported right frontostriatal atrophy and sub-
tle magnetic resonance imaging (MRI) changes in the left
hippocampus among patients with resistant depression.
25
A single photon emission computed tomography
(SPECT) found a significant increase in hippocampus-
amygdala activity in TRD patients compared with non-
TRD patients and healthy controls.
26A positron emission
tomography (PET) study of depressed patients with TRD,
non-TRD,and control subjects found that rostral anterior
cingulate metabolism uniquely differentiated eventual
treatment responders from nonresponders;nonrespon-
ders showed hypometabolism and responders showed
hypermetabolism compared with controls.
27The authors
reported that cingulate hypometabolism may represent
an important adaptive response to depression and failure
of this response may underlie poor outcome.
27
Impact of TRD
TRD is associated with extensive use of depression-related
and general medical services and poses a substantial eco-
nomic burden. A naturalistic, retrospective analysis of
medical claims data by Crown and colleagues found that
treatment-resistant patients were at least twice as likely to
be hospitalized (general medical and depression related)
and had at least 12% more outpatient visits.
15Treatment
resistance was also associated with use of 1.4 to 3 times
more psychotropic medications (including antidepres-
sants).Patients in the hospitalized TRD group had over 6
times the mean total medical costs of non-TRD patients
(US$ 42 344 versus US$ 6512) and their total depression-
related costs were 19 times greater than those of patients
in the comparison group (US$ 28 001 versus US$ 1455).
15
These findings emphasize the need for early identification
and effective long-term maintenance strategies for TRD.
Approaches in the management of TRD
General principles 
The general principles of the management of TRD are
outlined in Table I.
Antidepressant treatment strategies
Increasing the dose of antidepressant
Increasing the dose of antidepressant is a common strat-
egy for patients who have not responded to an adequate
trial with a selective serotonin reuptake inhibitor
(SSRI).
28 In patients who had not responded to fluoxe-
tine 20 mg/day,Fava and colleagues showed that raising
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55the dose of fluoxetine to 40 to 60 mg/day was significantly
more effective than adding desipramine 25 to 50 mg/day
or lithium 300 to 600 mg/day.
29 No guidelines exist regard-
ing the adequate duration of higher-dose antidepressant
treatment, but 6 weeks is likely to be sufficient.
30
Following response,treatment at the same dose can be
maintained for 6 to 9 months,followed by tapering of the
dose;if the patient has a history of recurrent or chronic
depression,then a longer duration of treatment must be
considered.
30
Augmentation strategies
Augmentation involves adding another agent to an ongo-
ing antidepressant treatment that has failed.Lithium aug-
mentation is a commonly used strategy to treat resistant
depression,with a long history of small controlled trials
and anecdotal reports on benefits of lithium augmenta-
tion.
31,32
Thyroid hormone augmentation of antidepressants has
been reported since the late 1960s. Altshuler and col-
leagues summarized the early literature on triiodothyro-
nine (T3), mainly small studies carried out many years
ago,demonstrating an acceleration of time to response
to antidepressants.
33 In a more recent trial, Lasser and
Baldessarini also showed an accelerated response to the
combination of TCA and T3.This study showed a bene-
fit of T3 used to augment partial or incomplete response
to TCA monotherapy.
34
Stimulants such as amphetamine,methylphenidate,and
pemoline,if used judiciously,and taken responsibly,can
be effective in achieving a quicker response in patients
with resistant depression. These should be avoided in
patients with a history of substance abuse and patients
should be informed about the potential,though minimal,
risk of developing tolerence.
35-37 There has also more
recent interest in exploring modafanil for TRD.
38
Evidence indicates that dopamine may have a role in the
pathogenesis of depression.
39 Dopaminergic agents such
as bromocriptine, pergolide, and pramipexole are
reported to be useful adjuncts for patients with TRD.
40
The serotonin-dopamine receptor antagonism of atypi-
cal antipsychotics has been suggested as a possible mech-
anism for the antidepressant action of atypical antipsy-
chotics. Recent studies have found that atypical
antipsychotics may produce an antidepressant effect in
schizophrenia and may be used either as an adjunctive
medication or as an alternative to mood stabilizers in
patients with affective disorders.
41 Treatment-resistant
psychotic depression is shown to be successfully treated
with clozapine.
42The addition of risperidone to an SSRI
among nonpsychotic depressed patients led to a rapid
response among patients who had not responded to
either fluoxetine or paroxetine treatment.
43A combina-
tion of olanzapine and fluoxetine showed superior effi-
cacy to either olanzapine or fluoxetine monotherapy in
patients with treatment-resistant depressive disorder
without psychotic features.
44The presence of psychotic
features,delusional depression,and bipolar depression
may be indications for the use of atypical antipsychotics.
7
Other augmentation strategies include buspirone,pindolol,
venlafaxine,mirtazapine,tianeptine,benzodiazepines,and
anticonvulsant augmentation of antidepressants.
30
Combination strategies
This involves the addition to an antidepressant of a com-
pound with a well-established efficacy as a single agent
in the treatment of depression.
30 Combination strategies
include TCAs and SSRIs,TCAs and MAOIs,bupropion
and SSRIs,anticonvulsants and antidepressants,and ben-
zodiazepines and antidepressants.
5 However,SSRIs,ven-
lafaxine,or clomipramine should not be combined with
MAOIs and the MAOI and TCA combination should be
used with caution.
Switching strategies
Switching involves stopping the antidepressant to which
the patient is not responding and switching to another
antidepressant,usually from a different class.
45 Switching
to an alternative antidepressant from a different class for
SSRI nonresponders may be helpful.
5 The options for
SSRI nonresponders include using bupropion, nefa-
zodone,venlafaxine,tianeptine,and mirtazapine.MAOIs
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Table I. General principles for the management of treatment-resistant
depression.
Ensure accurate diagnosis, including subtype of depression
Assess comorbid psychiatric and medical conditions
Evaluate psychosocial stressors and enhance social support
Ensure adequate dose and duration of treatment
Monitor and treat adverse events
Educate the patient regarding depression and antidepressants
Ensure compliance
Aim for remission may be used in TCA- or SSRI-resistant patients.
However,dietary restrictions are essential and an appro-
priate washout period is required after SSRI discontinu-
ation before initiating treatment with MAOIs.
Other treatment modalities
Electroconvulsive therapy
ECT is a potent,though underutilized,option for resistant
depression.A substantial amount of research has demon-
strated the short-term efficacy and safety of ECT in the
acute setting.It must be considered in depressed patients
who are suicidal,psychotic,or pregnant,or have a med-
ical illness.
46,47 However,a complete medical history and a
thorough physical examination is required to assess the
risks of anesthesia,and cardiovascular and neurological
adverse events associated with ECT.It is also important
to be aware of the potential drug–ECT interactions,espe-
cially in medically ill or elderly patients who are on con-
comitant medication.
48 Common adverse events associ-
ated with ECT are headache, temporary confusion,
delirium, and transient memory impairment.
49-51
Interestingly,nonresponse to pharmacotherapy is highly
associated with nonresponse to ECT.
52
Newer biological approaches
These include repetitive transcranial magnetic stimula-
tion (rTMS)
53 and vagus nerve stimulation,
54 which have
been proposed as alternatives to ECT and are currently
under investigation.
Novel psychopharmacological agents
Novel psychopharmacological agents for resistant depres-
sion include S-adenosylmethionine (SAMe),second-mes-
senger system modulators (inositol),and neuroendocrine
system–modulating agents,eg,dexamethasone.
55
Cognitive behavioral therapy
The purpose of cognitive behavioral therapy (CBT) is to
help patients understand the inaccuracy of their cogni-
tive assumptions and learn new ways and strategies of
dealing with issues.CBT is a short-term,structured ther-
apy,which involves active collaboration between patient
and therapist to achieve therapeutic goals;these are ori-
ented toward current problems and their resolution.A
trial of CBT may be considered in patients with TRD,
perhaps with modifications in treatment planning to take
into account its complexity.
56,57
Evidence-based algorithm
Where does all this leave us with respect to TRD? In gen-
eral, we have good data on acute treatment, suggestive
data on some second-level strategies, and good data on
ECT as a final step in a treatment strategy.This is far from
ideal and not typical of many other areas of medicine,such
as cardiology and oncology.A clear priority for our field is
the development of an empirically validated treatment
algorithm,with clear evidence that guides the choice of
approaches at any point in the treatment process.
One approach to this is a clinical trial called STAR*D
(Sequenced Treatment Alternatives to Relieve
Depression) (Figure 1).
58,59The STAR*D trial will enroll
more than 4000 adults with major depression in the
USA.They will be treated openly and aggressively in
level 1 for up to 12 weeks with SSRI (citalopram)
monotherapy.Those who achieve remission will be fol-
lowed naturalistically for 12 months. Using an innova-
tive statistical procedure called “equipoise randomiza-
tion,”
60 those who do not achieve a satisfactory response
will be randomized in level 2 to 1 of 7 treatments: 4
switch options (venlafaxine, sertraline, bupropion, or
cognitive therapy) and 3 augment options (cognitive
therapy, bupropion, or buspirone added to the citalo-
pram).Thus, in level 2 we will assess the benefit of the
different strategies (switch or augment) and will com-
pare the benefit of individual treatment options within
and between these strategies.Those with a satisfactory
response will be followed naturalistically for 12 months.
Those who do not have a satisfactory response will
enter level 3. In level 3, we compare 2 switch options
(mirtazapine or nortriptyline) and 2 augment options
(T3 and lithium).Those who remit will be followed and
those remaining will enter level 4 in which we compare
2 additional switch options: tranylcypromine and the
combination of mirtazapine and venlafaxine.The design
is summarized in reference 59 and is reproduced in
Figure 1.
Details of the design and rationale have been published
elsewhere
58;basically the study is being carried out in 12
sites throughout the USA. Each site serves as the hub
for as many as 4 clinics with both primary care practices
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enrolled in STAR*D in July 2001 and so the results will
not be available for several years.
Conclusions
Treatment-resistance is highly prevalent in depression;
it is costly and is associated with extensive use of
depression-related and general medical services. It
poses unique therapeutic challenges and dilemmas in
its management.
Early identification and the use of effective long-term
maintenance strategies are important. Decisions
regarding treatment,including increase in dosage,anti-
depressant augmentation,switching to a different class
of antidepressants, combination strategies, or other
biological treatments and psychotherapeutic treat-
ments should be made appropriately in the course of
illness.Although no definite algorithm exists for treat-
ing resistant depression, research in this area has
advanced considerably in recent years. This has the
potential to enhance our understanding about the
diagnostic and therapeutic aspects of TRD, to sub-
stantially reduce disability in this condition, and to
enhance the quality of life of individuals with this con-
dition. ❏
Pharmacological aspects
58
Level 
4
Switch to: tranylcypromine or mirtazapine combined with venlafaxine (extended-release)
Level 
3
Switch to: mirtazapine or nortriptyline
Or augment with: lithium or nortriptyline (only with bupropion [sustained-release], sertraline, 
venlafaxine [extended-release])
(Only for those receiving cognitive therapy in level 2)
Switch to: bupropion (sustained-release) or venlafaxine (extended-release)
Level 
2a
Switch to: bupropion (sustained-release), cognitive therapy, sertraline, 
venlafaxine (extended-release)
Or augment with: bupropion (sustained-release), buspirone, cognitive therapy
Level 
2
Level 
1
Initial treatment: citalopram
STAR*D Algorithim
Figure 1. STAR*D (Sequenced Treatment Alternatives to Relieve Depression) algorithm.
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Reproduced from reference 59: Rush AJ, Trivedi M, Fava M. Depression IV: STAR*D treatment trial for depression. [Images in Neuroscience]. 
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Perspectivas actuales en el manejo de la
depresión resistente al tratamiento
Los trastornos depresivos constituyen una de las
principales causas de discapacidad en el mundo y
tienen un gran impacto en la morbilidad, en la uti-
lización de servicios de salud y en los costos médicos.
La depresión mayor que no se resuelve con un ade-
cuado tratamiento antidepresivo se denomina
depresión resistente al tratamiento (DRT). No existe
una definición de DRT que sea aceptada universal-
mente y se han sugerido algunos criterios para defi-
nirla. Múltiples factores pueden contribuir a la resis-
tencia al tratamiento, incluyendo la comorbilidad
médica o psiquiátrica no reconocida, tratamiento
concomitante, la falta de adherencia y los estreso-
res psicosociales. La DRT se asocia con una amplia
utilización de servicios médicos generales y los rela-
cionados con depresión, e implica una significativa
carga económica. Las aproximaciones actuales a su
manejo incluyen el empleo de estrategias antide-
presivas, como el aumento de la dosis de antide-
presivos, cambios de tratamiento, estrategias de
potenciación, asociaciones de tratamientos, terapia
electroconvulsiva y terapia cognitivo conductual.
Aunque no existe un algoritmo definitivo para tra-
tar la DRT, la investigación en esta área ha avanzado
considerablemente en los años recientes. Una apro-
ximación a esto es el ensayo clínico STAR*D
(Sequenced Treatment Alternatives to Relieve
Depression). Este proyecto tiene el potencial de
aumentar nuestro conocimiento acerca de los aspec-
tos diagnósticos y terapéuticos de la DRT, de reducir
significativamente la discapacidad y de elevar la cali-
dad de vida de los individuos con esta condición.
Perspectives actuelles dans la prise en charge
de la dépression résistant au traitement
Les troubles dépressifs sont une cause majeure d’in-
capacité à travers le monde et ont un fort impact sur
la morbidité, la consommation des services médi-
caux et les coûts médicaux. Une dépression majeure
qui ne se résout pas avec un traitement antidépres-
seur adapté est dite « dépression résistant au trai-
tement » (DRT). Il n’y a pas de définition de la DRT
universellement acceptée et plusieurs critères ont
été suggérés pour la définir. De nombreux facteurs
peuvent contribuer à la résistance au traitement,
tels qu’une pathologie médicale ou psychiatrique
associée méconnue, la prise d’autres médicaments,
la non-observance du traitement et des facteurs psy-
chosociaux de stress. La DRT est associée à une
consommation importante de services tant en
médecine générale que spécifiquement liés à la
dépression, et représente de ce fait une charge éco-
nomique importante. La conduite à tenir actuelle
devant une DRT fait appel à toute une gamme de
stratégies antidépressives : augmentation de la dose
de l’antidépresseur ; stratégies de potentialisation,
d’association et de substitution ; électrochocs ; et
thérapie cognitivocomportementale. Bien qu’aucun
algorithme défini n’existe pour traiter la DRT, la
recherche dans ce domaine a considérablement pro-
gressé ces dernières années.  Une des approches est
une étude clinique appelée STAR*D (Sequenced
Treatment Alternatives to Relieve Depression). Celle-
ci devrait permettre d’approfondir notre compré-
hension des aspects thérapeutiques et diagnostiques
de la DRT, réduire considérablement l’incapacité et
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